Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) are newer agents that were initially developed for the treatment of diabetes. Here, GLP1R is linked to diabetes mellitus.